8th Annual Wolfe Research Healthcare Conference
Logotype for Natera Inc

Natera (NTRA) 8th Annual Wolfe Research Healthcare Conference summary

Event summary combining transcript, slides, and related documents.

Logotype for Natera Inc

8th Annual Wolfe Research Healthcare Conference summary

10 Nov, 2026

Leadership transition

  • Solomon, an early hire in 2011, led functions across women’s health, product development and clinical genomics; he helped create Prospera and was Signatera’s original general manager.

  • CFO said the immediate CEO handoff avoids unclear decision authority during 2027 budget-setting; Steve remains available through a consulting agreement and will advise the leadership team.

  • Commercial leadership, operating cadence, territory sizing and performance measures are expected to remain consistent; existing women’s health and oncology teams remain in place.

Revenue target and Signatera economics

  • A $6B revenue target for 2029 was presented as an achievable goal with good execution; 2026 revenue is expected to exceed $3B, with revenue intended to double by 2029.

  • Signatera ASP was $1,290; a $1,450 ASP by 2029 could be supported by Medicare and MolDx coverage decisions, improved Medicare Advantage reimbursement and commercial biomarker-state reimbursement.

  • Eleven tumor-type dossiers have been submitted to MolDx, including liver cancer, with roughly 10 submissions remaining; further prospective outcomes data may support additional NCCN and guideline coverage by 2029.

  • A Signatera volume waterfall incorporates repeat tests, new patient additions and patient retention; a reasonable scenario at $1,450 ASP could put total revenue above $6B in 2029.

  • ASP and volume growth need not be linear; repeat testing tends to make volume progression more linear, while ASP may include step-ups or flatter periods.

Signatera market and competition

  • The US cancer-incidence-based model implies ~20M annual tests: ~2M diagnoses yearly multiplied by ~10 tests per patient over a typical five-year cancer journey.

  • Applying conservative stage-based haircuts and a long-term $2,000 ASP, supported by broader coverage and lower contracted rates, yields an estimated $20B-$40B Signatera TAM.

  • CFO described a potential path to 90%+ physician penetration, contingent on improving the product and continuing ambitious prospective outcomes trials.

  • Competitive response centers on ongoing product improvements and evidence investment; ultra-sensitive Signatera is intended to supersede the exome-based version over time, alongside a tumor-naive MRD test for selected patients.

  • Five-year outcomes data are available; continued investment aims to extend the evidence lead, with 10-year data expected in five years if current progress continues.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Natera